>>I had forgot about maxy-alpha getting into p1. This is their only internally invented maxy shuffled compound to have entered the clinic. Study halted early in phase 1a, placed on hold.<<
From what I can see, MAXY-G34 was internally developed by Maxygen.
>>I guess if they had it over again they would have spun off the therapeutic arm and kept Codexis and everything else.<<
Yeah. At the time, I felt they were spinning off the most promising parts of their business and that going into drup development was an expensive mistake designed to feed the WS machine.
In a 2009 discussion on this board, you, microcapfun, and I wondered how much MAXY’s gene-shuffling technology was worth.
The answer, evidently, is not much—the effective price of today’s deal is even less than $20M because CDXS’ royalty obligations to MAXY have now been canceled.